A Case of Persistent Helicobacter pylori Infection Occurring with Anti-IgE Immunosuppression

The increasingly widespread use of novel immunosuppressive drugs may lead to unexpected infectious complications. We report a case of persistent Helicobacter pylori (H. pylori) infection that failed to respond to antimicrobial therapy in a patient receiving omalizumab (Xolair™, Genentech USA Inc., S...

Descripción completa

Detalles Bibliográficos
Autores principales: Zandman, Daniel, Hahn, William, Moss, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Gastroenterology 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435255/
https://www.ncbi.nlm.nih.gov/pubmed/26157810
http://dx.doi.org/10.14309/crj.2013.8
Descripción
Sumario:The increasingly widespread use of novel immunosuppressive drugs may lead to unexpected infectious complications. We report a case of persistent Helicobacter pylori (H. pylori) infection that failed to respond to antimicrobial therapy in a patient receiving omalizumab (Xolair™, Genentech USA Inc., San Francisco, CA and Novartis Pharmaceuticals, Basel, Switzerland), an anti-IgE monoclonal antibody approved by the FDA for treatment of severe persistent asthma. To our knowledge, this is the first case report linking an immunosuppressive regimen containing anti-IgE biologic therapy to persistent H. pylori infection.

Ejemplares similares